DEFECTIVE MACROPHAGE MIGRATION PRODUCED BY NEOPLASMS: IDENTIFICATION OF AN INHIBITOR OF MACROPHAGE CHEMOTAXIS1

[1]  R. Snyderman,et al.  Effects of neoplasms on inflammation: depression of macrophage accumulation after tumor implantation. , 1976, Journal of immunology.

[2]  M. R. Mickey,et al.  Defective monocyte function in patients with genitourinary carcinoma. , 1975, Journal of the National Cancer Institute.

[3]  M. Smith,et al.  Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts. , 1975, Journal of immunology.

[4]  R. Snyderman,et al.  Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity , 1975, Infection and immunity.

[5]  R. Snyderman,et al.  Depression of macrophage chemotaxis in vivo in tumor bearing mice. , 1975 .

[6]  F. Jacob,et al.  Antiinflammatory effects of murine malignant cells. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Lala.  DYNAMICS OF LEUKOCYTE MIGRATION INTO THE MOUSE ASCITES TUMOR , 1974, Cell and tissue kinetics.

[8]  E. Leonard,et al.  Abnormal monocyte chemotactic response in cancer patients. , 1974, Journal of the National Cancer Institute.

[9]  P. Ward,et al.  Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. , 1974, The New England journal of medicine.

[10]  J. Cerottini,et al.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. , 1974, Advances in immunology.

[11]  E. Wheelock,et al.  The role of macrophages in defense against neoplastic disease. , 1974, Advances in cancer research.

[12]  I. Bernstein.  Immunologic defenses against cancer. , 1973, The Journal of pediatrics.

[13]  R. Snyderman,et al.  A human mononuclear leukocyte chemotactic factor: characterization, specificity and kinetics of production by homologous leukocytes. , 1973, Journal of immunology.

[14]  R. Snyderman,et al.  Human mononuclear leukocyte chemotaxis: a quantitative assay for humoral and cellular chemotactic factors. , 1972, Journal of immunology.

[15]  D. Nelson,et al.  Macrophages As Effectors Of Cell-Mediated Immunity , 2020, Phagocytes and Cellular Immunity.

[16]  R. Snyderman,et al.  BIOLOGICAL ACTIVITY OF COMPLEMENT IN VIVO , 1971, The Journal of experimental medicine.

[17]  B. Zbar,et al.  Two-step mechanism of tumor graft rejection in syngeneic guinea pigs. II. Initiation of reaction by a cell fraction containing lymphocytes and neutrophils. , 1970, Journal of the National Cancer Institute.

[18]  K. Hellström,et al.  Immunological enhancement as studied by cell culture techniques. , 1970, Annual review of microbiology.

[19]  Graham Jb,et al.  TOLERANCE AGENT IN HUMAN CANCER. , 1964 .